Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor

References

• Lucas AJ, Olin JL, Coleman MD. Management and preventive measures for febrile neutropenia. P & T. 2018;43(4):228–232.
   PubMedGoogle Scholar
• Taplitz RA, Kennedy EB, Bow EJ, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American society of clinical oncology and infectious diseases society of America clinical practice guideline update. J Clin Oncol. 2018;36(14):1443–1453. doi:10.1200/JCO.2017.77.6211
   PubMed Web of Science ®Google Scholar
• Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO clinical practice guidelines†. Ann Oncol. 2016;27:v111–v118. doi:10.1093/annonc/mdw325
   PubMed Web of Science ®Google Scholar
• van der Velden WJFM, Herbers AHE, Netea MG, et al. Mucosal barrier injury, fever and infection in neutropenic patients with cancer: introducing the paradigm febrile mucositis. Br J Haematol. 2014;167(4):441–452. doi:10.1111/bjh.13113
   PubMed Web of Science ®Google Scholar
• Netea MG, Kullberg BJ, Blok WL, et al. The role of hyperuricemia in the increased cytokine production after lipopolysaccharide challenge in neutropenic mice. Blood. 1997;89(2):577–582. doi:10.1182/blood.V89.2.577
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS. Neutropenia: etiology and pathogenesis. Clin Cornerstone. 2006;8:S5–S11. doi:10.1016/S1098-3597(06)80053-0
   PubMedGoogle Scholar
• Pagano L, Caira M, Nosari A, et al. Etiology of febrile episodes in patients with acute myeloid leukemia: results from the hema e-chart registry. Arch Intern Med. 2011;171(16):1502–1503. doi:10.1001/archinternmed.2011.374
   PubMedGoogle Scholar
• Weycker D, Li X, Edelsberg J, et al. Risk and consequences of chemotherapy-induced febrile neutropenia in patients with metastatic solid tumors. J Oncol Pract. 2015;11(1):47–54.
   PubMed Web of Science ®Google Scholar
• Weycker D, Barron R, Kartashov A, et al. Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings. J Oncol Pharm Pract. 2014;20(3):190–198. doi:10.1177/1078155213492450
   PubMed Web of Science ®Google Scholar
• Kanamaru A, Tatsumi Y. Microbiological data for patients with febrile neutropenia. Clin Infect Dis. 2004;39(Supplement_1):S7–S10. doi:10.1086/383042
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Clark OA, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol. 2005;23(18):4198–4214. doi:10.1200/JCO.2005.05.645
   PubMed Web of Science ®Google Scholar
• Clark OAC, Lyman GH, Castro AA, et al. Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol.. 2005;23(18):4198–4214.
   PubMed Web of Science ®Google Scholar
• Mhaskar R, Clark OA, Lyman G, et al. Colony‐stimulating factors for chemotherapy‐induced febrile neutropenia. Cochrane Database Syst Rev. 2014;10.
   Web of Science ®Google Scholar
• Brito-Zerón P, Soria N, Muñoz S, et al. Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sjögren’s syndrome. Semin Arthritis Rheum. 2009;38(5):389–395. doi:10.1016/j.semarthrit.2008.01.014
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Bodey GP. Infections in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer. 1981;47(4):801–805. doi:10.1002/1097-0142(19810215)47:4<801::AID-CNCR2820470428>3.0.CO;2-6
   PubMed Web of Science ®Google Scholar
• Ogimi C, Krantz EM, Golob JL, et al. Antibiotic exposure prior to respiratory viral infection is associated with progression to lower respiratory tract disease in allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2018;24(11):2293–2301. doi:10.1016/j.bbmt.2018.05.016
   PubMed Web of Science ®Google Scholar
• Gui C, Cheng Z, Cecil E, et al. Low peripheral blood leukocyte counts during radiation therapy for head and neck cancer predict distant relapse and dysphagia. Int J Radiat Oncol Biol Phys. 2019;105(1):E421. doi:10.1016/j.ijrobp.2019.06.1530
   Web of Science ®Google Scholar
• Georgiadou SP, Sampsonas FL, Rice D, et al. Open-lung biopsy in patients with undiagnosed lung lesions referred at a tertiary cancer center is safe and reveals noncancerous, noninfectious entities as the most common diagnoses. Eur J Clin Microbiol Infect Dis. 2013;32(1):101–105. doi:10.1007/s10096-012-1720-9
   PubMed Web of Science ®Google Scholar
• Zheng B, Huang Z, Huang Y, et al. Predictive value of monocytes and lymphocytes for short-term neutrophil changes in chemotherapy-induced severe neutropenia in solid tumors. Supportive Care Cancer. 2020;28(3):1289–1294. doi:10.1007/s00520-019-04946-3
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Adelberg DE, Bishop MR. Emergencies related to cancer chemotherapy and hematopoietic stem cell transplantation. Emerg Med Clin North Am. 2009;27(2):311–331. doi:10.1016/j.emc.2009.01.005
   PubMed Web of Science ®Google Scholar
• Zheng B, Toarta C, Cheng W, et al. Accuracy of the Multinational Association of Supportive Care in Cancer (MASCC) and Clinical Index of Stable Febrile Neutropenia (CISNE) scores for predicting serious complications in adult patients with febrile neutropenia: a systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020;149:102922.
   PubMed Web of Science ®Google Scholar
• Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90(3):190–199. doi:10.1016/j.critrevonc.2013.12.006
   PubMed Web of Science ®Google Scholar
• Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study. Br J Haematol. 2009;144(5):677–685. doi:10.1111/j.1365-2141.2008.07514.x
   PubMed Web of Science ®Google Scholar
• Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003;44(12):2069–2076. doi:10.1080/1042819031000119262
   PubMed Web of Science ®Google Scholar
• Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003;98(11):2402–2409. doi:10.1002/cncr.11827
   PubMed Web of Science ®Google Scholar
• Crawford J, Glaspy JA, Stoller RG, et al. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005;3(1):36–46. doi:10.3816/SCT.2005.n.023
   PubMedGoogle Scholar
• Okishiro M, Kim SJ, Tsunashima R, et al. MDM2 SNP309 and TP53 R72P associated with severe and febrile neutropenia in breast cancer patients treated with 5-FU/epirubicin/cyclophosphamide. Breast Cancer Res Treat. 2012;132(3):947–953. doi:10.1007/s10549-011-1637-5
   PubMed Web of Science ®Google Scholar
• McLeod HL, Sargent DJ, Marsh S, et al. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from north American gastrointestinal intergroup trial N9741. J Clin Oncol. 2010;28(20):3227–3233.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Paesmans M, Rubenstein EB, et al. The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038–3051.
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Gómez J, González-Billalabeitia E, et al. Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients. Br J Cancer. 2011;105(5):612–617. doi:10.1038/bjc.2011.284
   PubMed Web of Science ®Google Scholar
• Carmona-Bayonas A, Jiménez-Fonseca P, Virizuela Echaburu J, et al. Prediction of serious complications in patients with seemingly stable febrile neutropenia: validation of the clinical index of stable febrile neutropenia in a prospective cohort of patients from the FINITE study. J Clin Oncol. 2015;33(5):465–471.
   PubMed Web of Science ®Google Scholar
• Coyne CJ, Le V, Brennan JJ, et al. Application of the MASCC and CISNE risk-stratification scores to identify low-risk febrile neutropenic patients in the emergency department. Ann Emerg Med. 2017;69(6):755–764. doi:10.1016/j.annemergmed.2016.11.007
   PubMed Web of Science ®Google Scholar
• Moriyama Y, Horita N, Kudo M, et al. Monocyte nadir is a possible indicator for neutrophil nadir during lung cancer chemotherapy. Clin Respir J. 2017;11(4):453–458. doi:10.1111/crj.12358
   PubMed Web of Science ®Google Scholar
• Shimanuki M, Imanishi Y, Sato Y, et al. Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget. 2018;9(27):18970–18984. doi:10.18632/oncotarget.24863
   PubMedGoogle Scholar
• Sato I, Nakaya N, Shimasaki T, Nakajima H, Motoo Y. Prediction of docetaxel monotherapy-induced neutropenia based on the monocyte percentage. Oncol Lett. 2012;3(4):860–864.
   PubMed Web of Science ®Google Scholar
• Ouyang W, Liu Y, Deng D, et al. The change in peripheral blood monocyte count: a predictor to make the management of chemotherapy-induced neutropenia. J Cancer Res Ther. 2018;14(Supplement):S565–s570. doi:10.4103/0973-1482.177502
   PubMed Web of Science ®Google Scholar
• Moreau M, Klastersky J, Schwarzbold A, et al. A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol. 2009;20(3):513–519. doi:10.1093/annonc/mdn655
   PubMed Web of Science ®Google Scholar
• Fonseca PJ, Carmona-Bayonas A, García IM, et al. A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. Br J Cancer. 2016;114(11):1191–1198. doi:10.1038/bjc.2016.118
   PubMed Web of Science ®Google Scholar
• Oguz A, Karadeniz C, Ckitak EC, et al. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia? Pediatr Hematol Oncol. 2006;23(2):143–151. doi:10.1080/08880010500457673
   PubMed Web of Science ®Google Scholar
• Lawrence SM, Corriden R, Nizet V. The ontogeny of a neutrophil: mechanisms of granulopoiesis and homeostasis. Microbiol Mol Biol Rev. 2018;82(1):e00057–17. doi:10.1128/MMBR.00057-17
   PubMed Web of Science ®Google Scholar
• Sallerfors B, Olofsson T. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) secretion by adherent monocytes measured by quantitative immunoassays. Eur J Haematol. 1992;49(4):199–207. doi:10.1111/j.1600-0609.1992.tb00047.x
   PubMed Web of Science ®Google Scholar
• Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014;25(4):355–367. doi:10.1016/j.cytogfr.2014.07.011
   PubMed Web of Science ®Google Scholar
• Castellani S, D’Oria S, Diana A, et al. G-CSF and GM-CSF modify neutrophil functions at concentrations found in cystic fibrosis. Sci Rep. 2019;9(1):12937. doi:10.1038/s41598-019-49419-z
   PubMed Web of Science ®Google Scholar
• Bober LA, Grace MJ, Pugliese-Sivo C, et al. The effect of GM-CSF and G-CSF on human neutrophil function. Immunopharmacology. 1995;29(2):111–119. doi:10.1016/0162-3109(94)00050-P
   PubMed Web of Science ®Google Scholar
• Fossati G, Mazzucchelli I, Gritti D, et al. In vitro effects of GM-CSF on mature peripheral blood neutrophils. Int J Mol Med. 1998;1(6):943–951.
   PubMed Web of Science ®Google Scholar
• Rutella S, Zavala F, Danese S, et al. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J Immunol. 2005;175(11):7085–7091. doi:10.4049/jimmunol.175.11.7085
   PubMed Web of Science ®Google Scholar
• Christopher MJ, Rao M, Liu F, et al. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med. 2011;208(2):251–260. doi:10.1084/jem.20101700
   PubMed Web of Science ®Google Scholar
• Saito M, Kiyokawa N, Taguchi T, et al. Granulocyte colony-stimulating factor directly affects human monocytes and modulates cytokine secretion. Exp Hematol. 2002;30(10):1115–1123. doi:10.1016/S0301-472X(02)00889-5
   PubMed Web of Science ®Google Scholar
• Cheng DE, Chang W-A, Hung J-Y, et al. Involvement of IL‑10 and granulocyte colony‑stimulating factor in the fate of monocytes controlled by galectin‑1. Mol Med Rep. 2014;10(5):2389–2394. doi:10.3892/mmr.2014.2573
   PubMed Web of Science ®Google Scholar